2022
DOI: 10.1080/22221751.2022.2117094
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 33 publications
0
2
0
Order By: Relevance
“…Several clinical trials have established the safety and some efficacy of mAb treatments [ 14 , 58 , 59 ], although optimal therapeutic efficacy generally requires early administration to COVID-19 patients [ 60 ]. Given the rapid and robust nature of the K18-hACE2 mouse model, antiviral activity of mAb treatment is often demonstrated in this model by administering the mAb prior to infection [ 48 , 49 , 50 , 52 ], although some mAb cocktails have shown significant anti-viral activity if given 24 h after infection [ 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…Several clinical trials have established the safety and some efficacy of mAb treatments [ 14 , 58 , 59 ], although optimal therapeutic efficacy generally requires early administration to COVID-19 patients [ 60 ]. Given the rapid and robust nature of the K18-hACE2 mouse model, antiviral activity of mAb treatment is often demonstrated in this model by administering the mAb prior to infection [ 48 , 49 , 50 , 52 ], although some mAb cocktails have shown significant anti-viral activity if given 24 h after infection [ 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…In the early phase of the pandemic, mAb treatment contributed to preventing a worsening of the disease and reducing hospitalisation and mortality rates [ 5 , 8 10 ]. In line with research on virus mutations, other antibodies were quickly developed to respond to virus mutations [ 8 , 11 ]. In particular, mAb treatment is used for early response to disease and is a vital option for some patients, including immunocompromised individuals, as it provides a prompt immune response [ 5 , 7 , 12 , 13 ].…”
Section: Introductionmentioning
confidence: 99%